Liposomal DQ in Combination with Copper Inhibits ARID1A Mutant Ovarian Cancer Growth.

Liposomal DQ in Combination with Copper Inhibits ARID1A Mutant Ovarian Cancer Growth.
复制标题

DOI:
10.3390/biom13050744
复制
发表时间:
2023-04-25
期刊:
影响因子:
5.5
通讯作者:
--
中科院分区:
生物学2区
文献类型:
--
作者:

文献摘要

参考文献

相似文献

arid1a突变卵巢癌的治疗策略是有限的。较高的基础活性氧(ROS)和较低的基础谷胱甘肽(GSH)增强了occc的侵袭性增殖能力和强转移性,这是由上皮-间质转化(EMT)标志物的增加和免疫抑制微环境所表明的。然而,异常的氧化还原稳态也增强了DQ-Lipo/Cu在突变细胞系中的敏感性。DQ是氨基甲酸二硫代酸衍生物,在ROS的作用下生成二硫代氨基甲酸酯(DDC), Cu与DDC的螯合作用进一步生成ROS,形成ROS级联反应。此外,DQ释放的醌(QM)靶向GSH的脆弱性;这种效应,加上活性氧的增加,破坏了氧化还原稳态,导致癌细胞死亡。同样重要的是,形成的Cu(DDC)2是一种有效的细胞毒性抗癌药物,可以成功诱导免疫原性细胞死亡(ICD)。EMT调控和ICD的协同作用将有助于控制癌症转移和可能的耐药。综上所述,我们的DQ-Lipo/Cu在肿瘤增殖、EMT标志物和“热”免疫反应中显示出有希望的抑制作用。
Therapeutic strategies for ARID1A-mutant ovarian cancers are limited. Higher basal reactive oxygen species (ROS) and lower basal glutathione (GSH) empower the aggressive proliferation ability and strong metastatic property of OCCCs, indicated by the increased marker of epithelial-mesenchymal transition (EMT) and serving the immunosuppressive microenvironment. However, the aberrant redox homeostasis also empowers the sensitivity of DQ-Lipo/Cu in a mutant cell line. DQ, a carbamodithioic acid derivative, generates dithiocarbamate (DDC) in response to ROS, and the chelation of Cu and DDC further generates ROS and provides a ROS cascade. Besides, quinone methide (QM) released by DQ targets the vulnerability of GSH; this effect, plus the increase of ROS, destroys the redox homeostasis and causes cancer cell death. Also importantly, the formed Cu(DDC)2 is a potent cytotoxic anti-cancer drug that successfully induces immunogenic cell death (ICD). The synergistic effect of EMT regulation and ICD will contribute to managing cancer metastasis and possible drug resistance. In summary, our DQ-Lipo/Cu shows promising inhibitory effects in cancer proliferation, EMT markers, and “heat” the immune response.
DOI: 10.1007/s11033-021-06671-9
发表时间: 2021-08-23
影响因子: 2.8
作者:
Erfani, Mehran;Zamani, Mozhdeh;Mokarram, Pooneh
通讯作者: Mokarram, Pooneh
DOI: 10.3390/cancers13030564
发表时间: 2021-02-02
期刊: Cancers
影响因子: 5.2
作者:
Mercogliano MF;Bruni S;Mauro F;Elizalde PV;Schillaci R
通讯作者: Schillaci R
DOI: 10.1038/ncb3582
发表时间: 2017-08
影响因子: 21.3
作者:
Bitler BG;Wu S;Park PH;Hai Y;Aird KM;Wang Y;Zhai Y;Kossenkov AV;Vara-Ailor A;Rauscher FJ III;Zou W;Speicher DW;Huntsman DG;Conejo-Garcia JR;Cho KR;Christianson DW;Zhang R
通讯作者: Zhang R
DOI: 10.1038/nm.3799
发表时间: 2015-03
期刊: Nature medicine
影响因子: 82.9
作者:
通讯作者: --
DOI: 10.1016/j.ccell.2019.02.009
发表时间: 2019-04-15
期刊: CANCER CELL
影响因子: 50.3
作者:
Cassetta, Luca;Fragkogianni, Stamatina;Pollard, Jeffrey W.
通讯作者: Pollard, Jeffrey W.